A preliminary evaluation of the effects of opioids on innate and adaptive human in vitro immune function

BMJ Supportive and Palliative Care

Volumn 4, Issue 4, 2014, Pages 357-367

  Boland, Jason W ^a,b   Foulds, Gemma A ^a   Ahmedzai, Sam H ^a   Graham Pockley, A ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; INTERLEUKIN 2; INTERLEUKIN 6; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TRAMADOL;

ADAPTIVE IMMUNITY; ADULT; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; PHAGOCYTOSIS; RESPIRATORY BURST;

ADAPTIVE IMMUNITY; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CODEINE; FENTANYL; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-2; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; METHADONE; MONOCYTES; MORPHINE; NEUTROPHILS; OXYCODONE; PHAGOCYTOSIS; RESPIRATORY BURST; TRAMADOL;

EID: 84906936976     PISSN: 2045435X     EISSN: 20454368     Source Type: Journal    
DOI: 10.1136/bmjspcare-2013-000573     Document Type: Article

References (49)

1. Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011;152:1139-45.
2. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often usedWorld Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313.
3. Borner C, Kraus J, Bedini A, et al. T-cell receptor/ CD28-mediated activation of human T lymphocytes induces expression of functional mu-opioid receptors. Mol Pharmacol 2008;74:496-504.
4. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. J Am Geriatr Soc 2011;59:1899-907.
5. Wang J, Barke RA, Charboneau R, et al. Morphine impairs host innate immune response and increases susceptibility to Streptococcus pneumoniae lung infection. J Immunol 2005;174:426-34.
6. Gaspani L, Bianchi M, Limiroli E, et al. The analgesic drug tramadol prevents the effect of surgery on natural killer cell activity and metastatic colonization in rats. J Neuroimmunol 2002;129:18-24.
7. Shavit Y, Ben-Eliyahu S, Zeidel A, et al. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. Neuroimmunomodulation 2004;11:255-60.
8. Sheen CH, Schleimer RP, Kulka M. Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy 2007;62:532-8.
9. Wang J, Charboneau R, Balasubramanian S, et al. The immunosuppressive effects of chronic morphine treatment are partially dependent on corticosterone and mediated by the mu-opioid receptor. J Leukoc Biol 2002;71:782-90.
10. Irwin M, Hauger RL, Brown M, et al. CRF activates autonomic nervous system and reduces natural killer cytotoxicity. Am J Physiol 1988;255(5 Pt 2):R744-7.
11. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879-923.
12. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010;24:83-95.
13. Franchi S, Moretti S, Castelli M, et al. Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav Immun 2012;26:480-8.
14. Banerjee S, Meng J, Das S, et al. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci Rep 2013;3:1977.
15. Stamer UM, Musshoff F, Kobilay M, et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007;82:41-7.
16. Jacobs R, Karst M, Scheinichen D, et al. Effects of fentanyl on cellular immune functions in man. Int J Immunopharmacol 1999;21:445-54.
17. Mercadante S, Villari P, Ferrera P, et al. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. J Palliat Med 2007;10:338-44.
18. Pesonen A, Suojaranta-Ylinen R, Hammaren E, et al. Comparison of effects and plasma concentrations of opioids between elderly and middle-aged patients after cardiac surgery. Acta Anaesthesiol Scand 2009;53:101-8.
19. Escher M, Daali Y, Chabert J, et al. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Clin Ther 2007;29:1620-31.
20. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239-49.
21. Kidd S, Brennan S, Stephen R, et al. Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. Arch Dis Child 2009;94:974-8.
22. Kim I, Barnes AJ, Oyler JM, et al. Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem 2002;48:1486-96.
23. Sacerdote P, Bianchi M, Gaspani L, et al. Effects of tramadol and its enantiomers on Concanavalin-A induced-proliferation and NK activity of mouse splenocytes: involvement of serotonin. Int J Immunopharmacol 1999;21:727-34.
24. Pan YX, Xu J, Xu M, et al. Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci USA 2009;106:4917-22.
25. Hopkinson K, Williams EA, Fairburn B, et al. A MitoTracker Green-based flow cytometric assay for natural killer cell activity: variability, the influence of platelets and a comparison of analytical approaches. Exp Hematol 2007;35:350-7.
26. Sheeran TP, Jackson FR, Dawes PT, et al. Measurement of natural killer cell cytotoxicity by area under a cytotoxic curve. A method suitable for rheumatoid arthritis. J Immunol Methods 1988;115:95-8.
27. Roy S, Barke RA, Loh HH. MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Brain Res Mol Brain Res 1998;61:190-94.
28. Szabo I, Rojavin M, Bussiere JL, et al. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther 1993;267:703-6.
29. Rojavin M, Szabo I, Bussiere JL, et al. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci 1993;53:997-1006.
30. Tubaro E, Santiangeli C, Belogi L, et al. Methadone vs morphine: comparison of their effect on phagocytic functions. Int J Immunopharmacol 1987;9:79-88.
31. Beilin B, Grinevich G, Yardeni IZ, et al. Tramadol does not impair the phagocytic capacity of human peripheral blood cells. Can J Anaesth 2005;52:1035-39.
32. Tubaro E, Avico U, Santiangeli C, et al. Morphine and methadone impact on human phagocytic physiology. Int J Immunopharmacol 1985;7:865-74.
33. Yeager MP, Procopio MA, DeLeo JA, et al. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg 2002;94:94-9.
34. Molitor TW, Murtaugh MP, Click RE, et al. Functional alterations of swine peripheral blood mononuclear cells by methadone. J Leukoc Biol 1992;51:124-8.
35. Weber RJ, Gomez-Flores R, Sora I, et al. Loss of morphine-induced suppression of NK cell activity and T-cell functions in mu opioid receptor knockout mice. Am J Immunol 2006;2:35-9.
36. Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004;110:385-92.
37. Van Der Laan JW, Timmerman H, Van Loveren H. Comparison of the in vivo effects of morphine and methadone on natural killer cell activity in spleen, peritoneal cavity, and lungs in rats. Int J Immunopharmacol 1996;18:401-07.
38. Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther 1989;250:606-10.
39. Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000;90:1411-14.
40. Thomas PT, Bhargava HN, House RV. Immunomodulatory effects of in vitro exposure to morphine and its metabolites. Pharmacology 1995;50:51-62.
41. Thomas PT, House RV, Bhargava HN. Direct cellular immunomodulation produced by diacetylmorphine (heroin) or methadone. Gen Pharmacol 1995;26:123-30.
42. House RV, Thomas PT, Bhargava HN. In vitro evaluation of fentanyl and meperidine for immunomodulatory activity. Immunol Lett 1995;46:117-24.
43. Martucci C, Franchi S, Lattuada D, et al. Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes. J Leukoc Biol 2007;81:344-54.
44. Liu Z, Gao F, Tian Y. Effects of morphine, fentanyl and tramadol on human immune response. J Huazhong Univ Sci Technolog Med Sci 2006;26:478-81.
45. Wang G, Weng Y, Ishiguro Y, et al. The effect of tramadol on serum cytokine response in patients undergoing pulmonary lobectomy. J Clin Anesth 2005;17:444-50.
46. Heikkila K, Ebrahim S, Rumley A, et al. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007;16:1155-9.
47. Eriksen CG, Olsen H, Husted LB, et al. The expression of IL-6 by osteoblasts is increased in healthy elderly individuals: stimulated proliferation and differentiation are unaffected by age. Calcif Tissue Int 2010;87:414-23.
48. Page GG. The immune-suppressive effects of pain. Adv Exp Med Biol 2003;521:117-25.
49. Ahmedzai SH. Personalized medicine-one size fits one: tailoring pain therapy to individuals' needs. J Pain Palliat Care Pharmacother 2013;27:83-5.